In conclusion, the results of our study strongly suggest that the polymorphisms within the IL-17A and IL-17F genes affect the susceptibility to RA, disease progression and response to treatment with anti-TNF inhibitors. This evidence concerns the gene IL17F and rheumatoid arthritis.